肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2017 欧洲临床实践建议：优化依鲁替尼治疗慢性淋巴细胞白血病患者的结局

2018-01-09 国外血液科相关专家小组 Br J Haematol. 2018 Jan 9.

依鲁替尼慢性淋巴细胞白血病

在欧洲，依鲁替尼被用于治疗几种B细胞恶性肿瘤，包括慢性淋巴细胞白血病。来袭欧洲的血液科专家小组针对依鲁替尼治疗慢性淋巴细胞白血病患者的相关问题提出了实践管理建议，内容涉及启动依鲁替尼治疗，治疗剂量，监测，同步治疗以及不良事件的管理等。

中文标题：

2017 欧洲临床实践建议：优化依鲁替尼治疗慢性淋巴细胞白血病患者的结局

英文标题：

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.

发布机构：

国外血液科相关专家小组

发布日期：

2018-01-09

简要介绍：

在欧洲，依鲁替尼被用于治疗几种B细胞恶性肿瘤，包括慢性淋巴细胞白血病。来袭欧洲的血液科专家小组针对依鲁替尼治疗慢性淋巴细胞白血病患者的相关问题提出了实践管理建议，内容涉及启动依鲁替尼治疗，治疗剂量，监测，同步治疗以及不良事件的管理等。

 

拓展指南：与白血病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2017 欧洲临床实践建议：优化依鲁替尼治疗慢性淋巴细胞白血病患者的结局)] GetToolGuiderByIdResponse(projectId=1, id=ebc321c0015a369b, title=2017 欧洲临床实践建议：优化依鲁替尼治疗慢性淋巴细胞白血病患者的结局, enTitle=Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice., guiderFrom=Br J Haematol. 2018 Jan 9., authorId=null, author=, summary=在欧洲，依鲁替尼被用于治疗几种B细胞恶性肿瘤，包括慢性淋巴细胞白血病。来袭欧洲的血液科专家小组针对依鲁替尼治疗慢性淋巴细胞白血病患者的相关问题提出了实践管理建议，内容涉及启动依鲁替尼治疗，治疗剂量，监测，同步治疗以及不良事件的管理等。 , cover=, journalId=null, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Tue Jan 09 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<p>在欧洲，依鲁替尼被用于治疗几种B细胞恶性肿瘤，包括慢性淋巴细胞白血病。来袭欧洲的血液科专家小组针对依鲁替尼治疗慢性淋巴细胞白血病患者的相关问题提出了实践管理建议，内容涉及启动依鲁替尼治疗，治疗剂量，监测，同步治疗以及不良事件的管理等。 </p> <p> </p>拓展指南：<strong>与<font color="red">白血病</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=401d91c00153e311" title="NCCN临床实践指南：慢性髓性白血病（2018.V3）" target="_blank">NCCN临床实践指南：慢性髓性白血病（2018.V3）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=96e6d1c001516e49" title="NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）" target="_blank">NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=d079b1c001516a82" title="NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2018.V2）" target="_blank">NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2018.V2）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=64b4c1c00151583f" title="2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤" target="_blank">2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=324af1c001512907" title="NCCN临床实践指南：慢性髓性白血病（2018.V2）" target="_blank">NCCN临床实践指南：慢性髓性白血病（2018.V2）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E7%99%BD%E8%A1%80%E7%97%85" target="_blank">有关白血病更多指南</a></ul>, tagList=[TagDto(tagId=21017, tagName=依鲁替尼), TagDto(tagId=4180, tagName=慢性淋巴细胞白血病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6540, appHits=99, showAppHits=9, pcHits=4905, showPcHits=3381, likes=105, shares=3, comments=9, approvalStatus=1, publishedTime=Sun Jan 14 22:16:02 CST 2018, publishedTimeString=2018-01-09, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 14 22:16:02 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 23:54:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 欧洲临床实践建议：优化依鲁替尼治疗慢性淋巴细胞白血病患者的结局)])
2017 欧洲临床实践建议：优化依鲁替尼治疗慢性淋巴细胞白血病患者的结局
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=278680, encodeId=fea22e868070, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Jan 15 09:33:16 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278678, encodeId=5e2a2e8678b4, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 15 09:33:06 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278666, encodeId=20fb2e8666c3, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 15 09:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278630, encodeId=6d402e863058, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Mon Jan 15 07:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278629, encodeId=81c12e8629cf, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 15 07:22:02 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 龙胆草

    学习谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=278680, encodeId=fea22e868070, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Jan 15 09:33:16 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278678, encodeId=5e2a2e8678b4, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 15 09:33:06 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278666, encodeId=20fb2e8666c3, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 15 09:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278630, encodeId=6d402e863058, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Mon Jan 15 07:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278629, encodeId=81c12e8629cf, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 15 07:22:02 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 Y—xianghai

    学习了新知识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=278680, encodeId=fea22e868070, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Jan 15 09:33:16 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278678, encodeId=5e2a2e8678b4, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 15 09:33:06 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278666, encodeId=20fb2e8666c3, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 15 09:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278630, encodeId=6d402e863058, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Mon Jan 15 07:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278629, encodeId=81c12e8629cf, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 15 07:22:02 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 明月清辉

    谢谢分享.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=278680, encodeId=fea22e868070, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Jan 15 09:33:16 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278678, encodeId=5e2a2e8678b4, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 15 09:33:06 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278666, encodeId=20fb2e8666c3, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 15 09:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278630, encodeId=6d402e863058, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Mon Jan 15 07:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278629, encodeId=81c12e8629cf, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 15 07:22:02 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 榄枷檬

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=278680, encodeId=fea22e868070, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Jan 15 09:33:16 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278678, encodeId=5e2a2e8678b4, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 15 09:33:06 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278666, encodeId=20fb2e8666c3, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 15 09:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278630, encodeId=6d402e863058, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Mon Jan 15 07:22:09 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278629, encodeId=81c12e8629cf, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 15 07:22:02 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0